Stockreport

Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis [Yahoo! F...

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF -- Real-world study of AYVAKIT highlights improvement across ISM symptoms -- -- 12 data presentations at 2026 AAAAI Annual Meeting reflect company's leadership in ele [Read more]